Tacrolimus therapy for refractory renal allograft rejection: experience with steroid withdrawal.
Cronin
D C
DC
Department of Surgery, University of Chicago, IL 60637, USA.
Bruce
D S
DS
Newell
K A
KA
Josephson
M A
MA
Millis
J M
JM
Piper
J B
JB
Ruebe
M
M
Kirby
M
M
Thistlethwaite
J R
JR
Woodle
E S
ES
D000328:Adult; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D003404:Creatinine / Q000097:blood; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology* / Q000473:pathology / Q000502:physiology; D016853:Muromonab-CD3 / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D016559:Tacrolimus / Q000627:therapeutic use*; D013997:Time Factors; D014184:Transplantation, Homologous
D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D003404:Creatinine; D011241:Prednisone; D016559:Tacrolimus